新生儿致命性肝血管瘤的内科治疗成功管理
本文报告2例新生儿致命性肝血管瘤,在拟评估肝移植前接受西罗莫司、糖皮质激素与普萘洛尔联合内科治疗并获得成功。肝血管瘤多为无症状自限性良性血管肿瘤,但复杂性病例在围产期存在显著并发症与死亡风险,且手术干预风险高,亟需有效内科治疗。
要点
- 新生儿肝血管瘤多为无症状自限性良性血管肿瘤。
- 复杂性肝血管瘤在围产期有显著并发症与死亡风险。
- 2例致命性病例经西罗莫司、糖皮质激素与普萘洛尔联合治疗成功。
核心结论
- 新生儿致命性肝血管瘤可经西罗莫司、糖皮质激素与普萘洛尔联合内科治疗获得成功,避免或推迟肝移植。
研究设计与样本
- 病例报告,纳入2例在肝移植评估前接受联合内科治疗的新生儿致命性肝血管瘤患儿。
主要发现
- 2例新生儿致命性肝血管瘤患儿在评估肝移植前接受联合内科治疗并治疗成功。
- 联合方案包括西罗莫司、糖皮质激素与普萘洛尔。
临床怎么用
- 对复杂性新生儿肝血管瘤,因手术干预并发症风险高,可考虑联合内科治疗。
- 西罗莫司、糖皮质激素与普萘洛尔联合方案可作为潜在选择,但需结合个案评估。
局限性
- 仅为2例病例报告,证据级别有限,不能据此推广至所有新生儿肝血管瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatic hemangioma (HH) is a common asymptomatic, self-limiting benign vascular tumor of the liver in neonates. Although complicated HHs are rare, they have significant risks of morbidity and mortality, especially during the perinatal period. Because of the high risks of complications from surgical interventions, there is an unmet need for effective medical therapy. We report 2 neonates with life-threatening HH who were evaluated for a liver transplant before being treated successfully with combined medical therapy, which included sirolimus, corticosteroids, and propranolol.
引用
- Lekwuttikarn R, Josephs S, Teng JM, et al. Successful Medical Management of Life-threatening Hepatic Hemangioma in Neonates. Pediatrics. 2019. PMID: 31511312. doi:10.1542/peds.2019-1339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。